Meeting
2019 Genitourinary Cancers Symposium
Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).
Authors
Aly-Khan A. Lalani
Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
Aly-Khan A. Lalani , Wanling Xie , Ronan Flippot , John A. Steinharter , Lauren Christine Harshman , Bradley Alexander McGregor , Daniel Yick Chin Heng , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 566)
DOI
10.1200/JCO.2019.37.7_suppl.566
Abstract #
566
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.
First Author: Joseph Clark
Poster
2020 Genitourinary Cancers Symposium
Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era.
First Author: E. Jason Abel
Poster
2015 Genitourinary Cancers Symposium
Survival comparison analysis of two historical cohorts of metastatic renal cell carcinoma patients (cytokine therapy versus targeted agents): A European single-center experience over 26 years.
First Author: Georg C. Hutterer
Poster
2015 Genitourinary Cancers Symposium
Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies: A single-institution experience.
First Author: Kamal Kishore Mandalapu